Safety and Immunogenicity of an mRNA Respiratory Syncytial Virus Vaccine, mRNA-1345, in Healthy and High-Risk Pediatric Populations Aged 2 to 17 Years

Clicks: 3
ID: 332665
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #295 of 297 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 297 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTI) in infants and children. No active RSV vaccine is currently available for children. mRNA-1345 is an investigational mRNA-based RSV vaccine encoding the prefusion F (preF) glycoprotein. Methods This phase 2, randomized, observer-blind study evaluated a single dose of mRNA-1345 in children aged 2 to <18 years who were healthy (2 to <5 years only) or had stable chronic conditions associated with increased RSV risk. Children aged 2 to <5 years received 7.5-, 15-, or 30-µg mRNA-1345 or placebo, whereas children aged 5 to <18 years received 15-, 30-, or 50-µg mRNA-1345. The primary objective was safety and reactogenicity (Part A); the secondary objective was immunogenicity. RSV surveillance was conducted from 6 to 12 months post-immunization in a subset of re-enrolled participants from the 2 to <5-year-old cohort (Part B). Results Overall, 346 participants received study vaccination. Across dose levels and age cohorts, mRNA-1345 was well tolerated, with no vaccine-related serious adverse events or discontinuations. mRNA-1345 elicited robust increases in RSV-A and RSV-B neutralizing antibody titers and preF-biased responses by Day 29. During Part B surveillance, RSV infections were infrequent, with no severe/hospitalized RSV-LRTIs. Conclusions mRNA-1345 demonstrated a favorable safety profile and was immunogenic in a predominantly RSV-seropositive pediatric population. These results support potential further clinical development of this vaccine in children aged >2 years at increased RSV risk, with further evaluation required to characterize the benefit-risk profile in RSV-naïve children.
Reference Key
openalex_W7222848431 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jennifer Moore, Hui Qian, Sonia Stoszek, Richard Bennett, Shelly David Senders, Scott P. Striplin, Jennifer Lynn Nayak, Matthew D. Snape
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag679
URL
https://doi.org/10.1093/ofid/ofag679
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.